<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24669278</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1838-7640</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>5</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Theranostics</Title><ISOAbbreviation>Theranostics</ISOAbbreviation></Journal><ArticleTitle>Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop.</ArticleTitle><Pagination><StartPage>498</StartPage><EndPage>513</EndPage><MedlinePgn>498-513</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7150/thno.7457</ELocationID><Abstract><AbstractText>Human enterovirus 71 (EV71) is the main causative agent of hand, foot, and mouth disease (HFMD) and is associated with several severe neurological complications in the Asia-Pacific region. Here, we evaluated that while passive transfer of neutralizing monoclonal antibody (nMAb) against the VP2 protein protect against lethal EV71 infection in BALB/c mice. Protective nMAb were mapped to residues 141-155 of VP2 by peptide ELISA. High-resolution structural analysis showed that the epitope is part of the VP2 EF loop, which is the "puff" region that forms the "southern rim" of the canyon. Moreover, a three-dimensional structural characterization for the puff region with prior neutralizing epitopes and receptor-binding sites that can serve to inform vaccine strategies. Interestingly, using hepatitis B virus core protein (HBc) as a carrier, we demonstrated that the cross-neutralizing EV71 antibodies were induced, and the VP2 epitope immunized mice serum also conferred 100% in vivo passive protection. The mechanism of in vivo protection conferred by VP2 nMAb is in part attributed to the in vitro neutralizing titer and ability to bind authentic viral particles. Importantly, the anti-VP2(aa141-155) antibodies could inhibit the binding of human serum to EV71 virions showed that the VP2 epitope is immunodominant. Collectively, our results suggest that a broad-spectrum vaccine strategy targeting the high-affinity epitope of VP2 EF loop may elicits effective immune responses against EV71 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Longfa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>1. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, 361102, PR China ; 2. National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen Fujian, 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Delei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>1. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, 361102, PR China ; 2. National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen Fujian, 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhiqun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>1. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Lisheng</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>1. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Miao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>2. National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen Fujian, 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Hai</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>1. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, 361102, PR China ; 2. National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen Fujian, 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yixin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>1. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, 361102, PR China ; 2. National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen Fujian, 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Que</LastName><ForeName>Yuqiong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>1. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, 361102, PR China ; 2. National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen Fujian, 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shih</LastName><ForeName>James Wai Kuo</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>1. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, 361102, PR China ; 2. National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen Fujian, 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>2. National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen Fujian, 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, 361102, PR China ; 2. National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen Fujian, 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Qinjian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>1. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, 361102, PR China ; 2. National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen Fujian, 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Tong</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>1. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, 361102, PR China ; 2. National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen Fujian, 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Ningshao</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>1. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, 361102, PR China ; 2. National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen Fujian, 361102, PR China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>02</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Theranostics</MedlineTA><NlmUniqueID>101552395</NlmUniqueID><ISSNLinking>1838-7640</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018985">Epitopes, B-Lymphocyte</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015678">Viral Structural Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018985" MajorTopicYN="N">Epitopes, B-Lymphocyte</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015678" MajorTopicYN="N">Viral Structural Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Human enterovirus 71</Keyword><Keyword MajorTopicYN="N">VP2 EF loop</Keyword><Keyword MajorTopicYN="N">cross-neutralizing linear epitope</Keyword><Keyword MajorTopicYN="N">epitope peptide vaccine.</Keyword><Keyword MajorTopicYN="N">therapeutic antibodies</Keyword></KeywordList><CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>12</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24669278</ArticleId><ArticleId IdType="pmc">PMC3964443</ArticleId><ArticleId IdType="doi">10.7150/thno.7457</ArticleId><ArticleId IdType="pii">thnov04p0498</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Patel KP, Bergelson JM. Receptors identified for hand, foot and mouth virus. Nat Med. 2009;15:728&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19584857</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagiwara A, Tagaya I, Yoneyama T. Epidemic of hand, foot and mouth disease associated with enterovirus 71 infection. Intervirology. 1978;9:60&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">202573</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishimaru Y, Nakano S, Yamaoka K, Takami S. Outbreaks of hand, foot, and mouth disease by enterovirus 71. High incidence of complication disorders of central nervous system. Arch Dis Child. 1980;55:583&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1627055</ArticleId><ArticleId IdType="pubmed">6254449</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9:1097&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Qian Y, Wang S, Serrano JM, Li W, Huang Z. et al. EV71: an emerging infectious disease vaccine target in the Far East? Vaccine. 2010;28:3516&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">20304038</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov M, Voroshilova M, Shindarov L, Lavrova I, Gracheva L, Koroleva G. et al. Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol. 1979;60:329&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">228639</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy G, Takatsy S, Kukan E, Mihaly I, Domok I. Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol. 1982;71:217&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">6285858</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, Alexander JP. et al. Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis. 2000;31:678&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">11017815</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY. Enterovirus 71 in Taiwan. Pediatr Neonatol. 2008;49:103&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">19054914</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardosa MJ, Perera D, Brown BA, Cheon D, Chan HM, Chan KP. et al. Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. Emerg Infect Dis. 2003;9:461&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2957976</ArticleId><ArticleId IdType="pubmed">12702227</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z. et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012;19:424&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG. Crystal Structure of Human Enterovirus 71. Science. 2012 doi:10.1126/science.1218713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann MG, Arnold E, Erickson JW, Frankenberger EA, Griffith JP, Hecht HJ. et al. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature. 1985;317:145&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">2993920</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 2007;125:61&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY. et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011;29:4362&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiore L, Ridolfi B, Genovese D, Buttinelli G, Lucioli S, Lahm A. et al. Poliovirus Sabin type 1 neutralization epitopes recognized by immunoglobulin A monoclonal antibodies. J Virol. 1997;71:6905&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC191973</ArticleId><ArticleId IdType="pubmed">9261417</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttinelli G, Donati V, Ruggeri FM, Joki-Korpela P, Hyypia T, Fiore L. Antigenic sites of coxsackie A9 virus inducing neutralizing monoclonal antibodies protective in mice. Virology. 2003;312:74&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">12890622</ArticleId></ArticleIdList></Reference><Reference><Citation>Bubeck D, Filman DJ, Cheng N, Steven AC, Hogle JM, Belnap DM. The structure of the poliovirus 135S cell entry intermediate at 10-angstrom resolution reveals the location of an externalized polypeptide that binds to membranes. J Virol. 2005;79:7745&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1143686</ArticleId><ArticleId IdType="pubmed">15919927</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J, Cheng N, Chow M, Filman DJ, Steven AC, Hogle JM. et al. An externalized polypeptide partitions between two distinct sites on genome-released poliovirus particles. J Virol. 2011;85:9974&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196412</ArticleId><ArticleId IdType="pubmed">21775460</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Lu J. Enterovirus 71 vaccine: close but still far. Int J Infect Dis. 2010;14:e739&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110504</ArticleId><ArticleId IdType="pubmed">20400350</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Macary PA, Alonso S, Poh CL. Identification of human CD4 T-cell epitopes on the VP1 capsid protein of enterovirus 71. Viral Immunol. 2008;21:215&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">18419256</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Chow VT, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 2007;9:1299&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiener TK, Jia Q, Lim XF, He F, Meng T, Chow VT. et al. Characterization and specificity of the linear epitope of the enterovirus 71 VP2 protein. Virol J. 2012;9:55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3307493</ArticleId><ArticleId IdType="pubmed">22361222</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1172191</ArticleId></ArticleIdList></Reference><Reference><Citation>Galfre G, Howe SC, Milstein C, Butcher GW, Howard JC. Antibodies to major histocompatibility antigens produced by hybrid cell lines. Nature. 1977;266:550&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">558524</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo WX, Zhang J, Yang HJ, Li SW, Xie XY, Pang SQ. et al. [Construction and application of an Escherichia coli high effective expression vector with an enhancer] Sheng Wu Gong Cheng Xue Bao. 2000;16:578&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">11191761</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang HJ, Chen M, Cheng T, He SZ, Li SW, Guan BQ. et al. Expression and immunoactivity of chimeric particulate antigens of receptor binding site-core antigen of hepatitis B virus. World J Gastroenterol. 2005;11:492&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4250797</ArticleId><ArticleId IdType="pubmed">15641132</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu F, Yan Q, Wang H, Niu J, Li L, Zhu F. et al. Performance of detecting IgM antibodies against enterovirus 71 for early diagnosis. PLoS One. 2010;5:e11388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2894942</ArticleId><ArticleId IdType="pubmed">20613983</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu F, He D, He S, Wu B, Guan L, Niu J. et al. Development of an IgM-capture ELISA for Coxsackievirus A16 infection. J Virol Methods. 2011;171:107&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">20970457</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YF, Chou CT, Lei HY, Liu CC, Wang SM, Yan JJ. et al. A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol. 2004;78:7916&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC446098</ArticleId><ArticleId IdType="pubmed">15254164</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CS, Yao YC, Lin SC, Lee YP, Wang YF, Wang JR. et al. Retrograde axonal transport: a major transmission route of enterovirus 71 in mice. J Virol. 2007;81:8996&#x2013;9003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1951457</ArticleId><ArticleId IdType="pubmed">17567704</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X, Ku Z, Liu Q, Wang X, Shi J, Zhang Y. et al. Chimeric Virus-Like Particle Vaccines Displaying Conserved Enterovirus 71 Epitopes Elicit Protective Neutralizing Antibodies in Mice through Divergent Mechanisms. J Virol. 2014;88:72&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3911748</ArticleId><ArticleId IdType="pubmed">24131712</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med. 2009;15:794&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T. et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med. 2009;15:798&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SL, Chou YT, Wu CN, Ho MS. Annexin II binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity. J Virol. 2011;85:11809&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3209289</ArticleId><ArticleId IdType="pubmed">21900167</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Song Z, Qi Y, Feng X, Xu N, Sun Y. et al. Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2. J Biol Chem. 2012;287:6406&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3307280</ArticleId><ArticleId IdType="pubmed">22219187</ArticleId></ArticleIdList></Reference><Reference><Citation>Che Z, Olson NH, Leippe D, Lee WM, Mosser AG, Rueckert RR. et al. Antibody-mediated neutralization of human rhinovirus 14 explored by means of cryoelectron microscopy and X-ray crystallography of virus-Fab complexes. J Virol. 1998;72:4610&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC109976</ArticleId><ArticleId IdType="pubmed">9573224</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao C, Bator CM, Bowman VD, Rieder E, He Y, Hebert B. et al. Interaction of coxsackievirus A21 with its cellular receptor, ICAM-1. J Virol. 2001;75:2444&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC114827</ArticleId><ArticleId IdType="pubmed">11160747</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao C, Bator-Kelly CM, Rieder E, Chipman PR, Craig A, Kuhn RJ. et al. The crystal structure of coxsackievirus A21 and its interaction with ICAM-1. Structure. 2005;13:1019&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">16004874</ArticleId></ArticleIdList></Reference><Reference><Citation>Belnap DM, McDermott BM Jr, Filman DJ, Cheng N, Trus BL, Zuccola HJ. et al. Three-dimensional structure of poliovirus receptor bound to poliovirus. Proc Natl Acad Sci U S A. 2000;97:73&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26618</ArticleId><ArticleId IdType="pubmed">10618373</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Bowman VD, Mueller S, Bator CM, Bella J, Peng X. et al. Interaction of the poliovirus receptor with poliovirus. Proc Natl Acad Sci U S A. 2000;97:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26619</ArticleId><ArticleId IdType="pubmed">10618374</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Chipman PR, Howitt J, Bator CM, Whitt MA, Baker TS. et al. Interaction of coxsackievirus B3 with the full length coxsackievirus-adenovirus receptor. Nat Struct Biol. 2001;8:874&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152846</ArticleId><ArticleId IdType="pubmed">11573093</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann MG, He Y, Kuhn RJ. Picornavirus-receptor interactions. Trends Microbiol. 2002;10:324&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">12110211</ArticleId></ArticleIdList></Reference><Reference><Citation>Page GS, Mosser AG, Hogle JM, Filman DJ, Rueckert RR, Chow M. Three-dimensional structure of poliovirus serotype 1 neutralizing determinants. J Virol. 1988;62:1781&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC253228</ArticleId><ArticleId IdType="pubmed">2451757</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamura K, Nishimura Y, Abo M, Wakita T, Shimizu H. Adaptive mutations in the genomes of enterovirus 71 strains following infection of mouse cells expressing human P-selectin glycoprotein ligand-1. J Gen Virol. 2011;92:287&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3081077</ArticleId><ArticleId IdType="pubmed">20943886</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke BE, Newton SE, Carroll AR, Francis MJ, Appleyard G, Syred AD. et al. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature. 1987;330:381&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">2446137</ArticleId></ArticleIdList></Reference><Reference><Citation>Schotsaert M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines. 2009;8:499&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2706389</ArticleId><ArticleId IdType="pubmed">19348565</ArticleId></ArticleIdList></Reference><Reference><Citation>Walther M, Dunachie S, Keating S, Vuola JM, Berthoud T, Schmidt A. et al. Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine. 2005;23:857&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">15603885</ArticleId></ArticleIdList></Reference><Reference><Citation>Milich DR, McLachlan A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science. 1986;234:1398&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">3491425</ArticleId></ArticleIdList></Reference><Reference><Citation>Pumpens P, Borisova GP, Crowther RA, Grens E. Hepatitis B virus core particles as epitope carriers. Intervirology. 1995;38:63&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">8666525</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010;9:767&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">20811384</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>